February 13, 2025

CBCC signed an MoU with iNGENū CRO, an Australia-based CRO

  CBCC Expands its Footprint in Australia to Accelerate Clinical Innovation! CBCC Global Research signed an MoU with iNGENū CRO, an Australia-based CRO focusing on providing high quality, FDA-compliant clinical trials. The MoU will enable US-based Innovative Biotech Firms to fast-track early-phase trials Advantages for US-based Biotech Firms: · An IND is not required before starting a Phase I / II trial in Australia · Reduce study start-up timeline by ~80% · Start patient recruitment in nearly 8 weeks · Average 4 weeks of IRB / HREC turnaround time To book a discovery call and know more, please write to us at: bd@cbcc.global CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION Manoj Vyas Dr. Sandeep Singh Jaimeen Vanparia Avanish Mishra, Ph.D. Sanjeev Ganatra Nikhil Gandhi Mark Kirschbaum Harakh Shah, PMP® Tapan Shah Kinnari Gandhi RQAP-GCP Dr. Praveen Choudhary Nikunj Patel Ankit Parikh Ajit Upadhyaya Ankit Pandav Devang Pandya Jay Vyas Udayan Vyas